← Eichor
Study identifier: NCT05238740 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

Condition: Spondylosis · Spondylolisthesis · Degenerative Disc Disease  ·  Sponsor: Lindenhofgruppe AG

PhaseNA
Planned participants168
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

The aim of this study is to prospectively investigate the potential for bony fusion of ViviGen® bone graft substitute in comparison to rhBMP-2 in monosegmental ALIF procedure L5/S1 and in monosegmental XLIF procedure L4/5

This description comes directly from the study's public registry record.

Talk to the study team

Diel Peter, Dr. med  ·  +41 31 358 17 90  ·  peter.diel@sonnenhof.ch

Sabine Berger  ·  +41 79 328 50 24  ·  sabine.berger@lindenhofgruppe.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Orthopädie SonnenhofBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05238740